Repositioning Candidate Details
| Candidate ID: | R0726 |
| Source ID: | DB05186 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | SQ-109 |
| Synonyms: | -- |
| Molecular Formula: | C22H38N2 |
| SMILES: | CC(C)=CCC\C(C)=C\CNCCNC1C2CC3CC(C2)CC1C3 |
| Structure: |
|
| DrugBank Description: | SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen. |
| CAS Number: | 502487-67-4 |
| Molecular Weight: | 330.5505 |
| DrugBank Indication: | Investigated for use/treatment in bacterial infection, infectious and parasitic disease (unspecified), and tuberculosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | With a mechanism of action distinct from other antibiotics used in TB therapy, SQ109 inhibits cell wall synthesis and acts on multiple cellular pathways in a select group of microorganisms. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|